PARP Inhibitors: Staying on Target?

Craig L Doig; Gareth G Lavery

doi:10.1016/j.chembiol.2016.12.003

PARP Inhibitors: Staying on Target?

Cell Chem Biol. 2016 Dec 22;23(12):1442-1443. doi: 10.1016/j.chembiol.2016.12.003.

Authors

Craig L Doig¹, Gareth G Lavery²

Affiliations

¹ Institute of Metabolism and Systems Research, University of Birmingham, 2(nd) Floor IBR Tower, Birmingham B15 2TT, UK; Centre for Endocrinology, Diabetes, and Metabolism, Birmingham Health Partners, Birmingham B15 2TH, UK.
² Institute of Metabolism and Systems Research, University of Birmingham, 2(nd) Floor IBR Tower, Birmingham B15 2TT, UK; Centre for Endocrinology, Diabetes, and Metabolism, Birmingham Health Partners, Birmingham B15 2TH, UK. Electronic address: g.g.lavery@bham.ac.uk.

PMID: 28009975
DOI: 10.1016/j.chembiol.2016.12.003

Abstract

Successful phase III trials with poly-ADP-ribose (PARP) inhibitors will have implications for stratified cancer therapy. In this issue of Cell Chemical Biology, Knezevic et al. (2016) demonstrate that the existing collection of PARP inhibitors each display distinctive protein interaction profiles, reaching beyond their intended therapeutic target, with implications for metabolic and other disease.